Exchange: NASDAQ·Updated 07:30 PM EST
ACRV logo

ACRV ACRIVON THERAPEUTICS INC

$1.20
$0.25
(17.86%)
Today
Closed $1.15
$0.045
(3.91%)
After Hours
Reported EarningsNov 16
Mkt Cap$49.35M
Vol1.29M

About ACRV

Acrivon Therapeutics, Inc. develops drugs for clinical treatment. Its unique precision medicine platform is Acrivon Predictive Precision Proteomics (AP3). AP3 is used to generate proprietary OncoSignature companion diagnostics to identify patients who will benefit from the medicine. The company was founded by Peter Blume-Jensen and Kristina Masson in 2018 and is headquartered in Watertown, MA.
48

Neutral Sentiment

How do you feel about ACRV?

blackpoint01
$ACRV this is going to be an important week, hopefully we get to see every small progress they have been making reflects on the stock price 😮‍💨 it has been too long of a wait.!
6
Bullbarbise
$ACRV Jefferies confirmed Acrivon target price 14,000$ after ACR-525 event. Now they have clear the strategy on acr-525
4
Dani_G_German
$ACRV this has all the ingredients for an epic blast off just do you have the patience while it cooks
4
Double_it_Helix
$ACRV Proprietary AP3 platform helps identify patients most likely to respond to treatments.h
3
Rayvio_News_Filter
$ACRV 🤝 Acrivon Therapeutics acquired ACR-525, a Phase 2-ready oral JAK1 inhibitor, and a preclinical PKCθ inhibitor program from Aqilion AB to expand into immunology and inflammation. Market-relevant event
3
focafoca99
$ACRV closed a cash asset purchase agreement to acquire Aqilion's oral JAK1 inhibitor program and PKCθ preclinical assets.
2
Bullbarbise
$ACRV perfect. November 20th for ACR2316. Now waiting for the Interim date. But possible that will be released on November 9th? We will see. The white horse ready to show somethyng impressive.
2
Rayvio_News_Filter
$ACRV 🤝 Acrivon Therapeutics, Inc. entered an asset purchase agreement with Aqilion AB to acquire oral JAK1 inhibitor programs, including ACR-525, and a PKCθ inhibitor preclinical program for inflammatory or autoimmune diseases. Curated for market relevance
1
Hosai
$ACRV What kind of ACR 368 results are people expecting later this month? I would guess at 37% orr in mono and 44% in combo arm. Maybe around 6 months duration. Obv they got 52% orr before in Jan but this was not pre-specified howver it's not terrible kind of post hoc as "makes sense" to look at this group. Therefore I don't give it a huge discount so to speak plus the broader results still decent but there would likely be some inflation. For safery already large database so fairly confident there. If they get this it should be enough for accelerated approval pathway (ceo said 30% orr would be enough I believe) and this being priced in as a reasonable prospect should easily warrant a $300 million market cap or over $7 a share, which does me slightly baffled by current sp especially when they have ok cash but is a bad market atm. Obv 2316 has it's own presentation later this month and looks intriguing too but earlier stage so harder to value.
1
99TouchGrass
$ACRV Did any data even come out today? Just read their website was this reflective off of the 2316 data?
blackpoint01
$ACRV so they don’t even have the news out and they are already preparing for an offering. Stupid.!
elmono
$ACRV market says F you to trash companies that distract and go on spending spree…. think they will generate disappointing data with lead program and therefore start other hobby projects….no good sign

Advertisement|Remove ads.